Literature DB >> 30247642

Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review.

Laura van Iersel1, Karen E Brokke2, Roger A H Adan3,4, Lauren C M Bulthuis2, Erica L T van den Akker5, Hanneke M van Santen1.   

Abstract

The development of hypothalamic obesity (HO) following craniopharyngioma (CP) and other suprasellar tumors leads to reduced patient quality of life. No treatment algorithms are currently available for management of HO. Depending on which hypothalamic nuclei are destroyed, the pathophysiologic mechanisms and clinical symptoms that contribute to HO differ among patients. Herein, we review the contribution of the hypothalamus to the pathophysiologic mechanisms and symptoms underlying CP-associated HO. Additionally, we performed a systematic search of MEDLINE and Embase to identify all intervention studies for weight management in patients with CP or other suprasellar tumors published until September 2017. The search yielded 1866 publications, of which 40 were included. Of these 40 studies, we identified four modalities for intervention (i.e., lifestyle, dietary, pharmacotherapeutic, or surgical) within six clinical domains (i.e., psychosocial disorders, hyperphagia, sleep disturbances, decreased energy expenditure, hyperinsulinemia, and hypopituitarism). We used the findings from our systematic review, in addition to current knowledge on the pathophysiology of HO, to develop an evidence-based treatment algorithm for patients with HO caused by CP or other suprasellar tumors. Although the individual effects of the HO interventions were modest, beneficial individual effects may be achieved when the pathophysiologic background and correct clinical domain are considered. These two aspects can be combined in an individualized treatment algorithm with a stepwise approach for each clinical domain. Recently elucidated targets for HO intervention were also explored to improve future management of HO for patients with CP and other suprasellar tumors.

Entities:  

Mesh:

Year:  2019        PMID: 30247642     DOI: 10.1210/er.2018-00017

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  20 in total

1.  Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007.

Authors:  Svenja Boekhoff; Brigitte Bison; Maria Eveslage; Panjarat Sowithayasakul; Hermann L Müller
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

2.  Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma.

Authors:  Mohammed A Fouda; David Zurakowski; R Michael Scott; Karen J Marcus; Peter E Manley; Nicole J Ullrich; Laurie E Cohen; Liliana C Goumnerova
Journal:  Childs Nerv Syst       Date:  2020-09-04       Impact factor: 1.475

Review 3.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

4.  Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study.

Authors:  T Feola; R Sa Pirchio; G Puliani; R Pofi; M Crocco; V Sada; F Sesti; F Verdecchia; D Gianfrilli; M Appetecchia; N Di Iorgi; M L Jaffrain-Rea; R Pivonello; A M Isidori; A B Grossman; E Sbardella
Journal:  J Endocrinol Invest       Date:  2022-08-24       Impact factor: 5.467

5.  Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review.

Authors:  Ramona Cordani; Marco Veneruso; Flavia Napoli; Natascia Di Iorgi; Claudia Milanaccio; Alessandro Consales; Nicola Disma; Elisa De Grandis; Mohamad Maghnie; Lino Nobili
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

6.  Postoperative MR imaging surveillance of pediatric craniopharyngioma: new institutional guidelines.

Authors:  Mohammed A Fouda; Emily L Day; Steven J Staffa; R Michael Scott; Karen J Marcus; Lissa C Baird
Journal:  Childs Nerv Syst       Date:  2020-10-03       Impact factor: 1.475

7.  Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.

Authors:  Jiska van Schaik; Dominique G A Begijn; Laura van Iersel; Yvonne Vergeer; Eelco W Hoving; Babette Peeters; Hanneke M van Santen
Journal:  Obes Facts       Date:  2020-08-11       Impact factor: 3.942

8.  Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.

Authors:  Manuela Cerbone; Harshini Katugampola; Helen L Simpson; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

9.  Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Authors:  Kim Huynh; Marianne Klose; Kim Krogsgaard; Jørgen Drejer; Sarah Byberg; Sten Madsbad; Faidon Magkos; Abdellatif Aharaz; Berit Edsberg; Jacob Tfelt-Hansen; Arne Vernon Astrup; Ulla Feldt-Rasmussen
Journal:  Eur J Endocrinol       Date:  2022-05-09       Impact factor: 6.558

Review 10.  Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.

Authors:  Ujendra Kumar; Sneha Singh
Journal:  Int J Mol Sci       Date:  2020-04-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.